

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 267 678
A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 87308130.1

(51) Int. Cl.4: **C12N 15/00** , **C12P 21/02** ,
C12N 5/00

(22) Date of filing: 15.09.87

The microorganism has been deposited with the
Agricultural Research Culture Collection under
number B - 18113.

(30) Priority: 15.09.86 US 907369

(43) Date of publication of application:
18.05.88 Bulletin 88/20

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: **Integrated Genetics, Inc.**
31 New York Avenue
Framingham Massachusetts 01701(US)

(72) Inventor: **Beck, Anton K.**
32 Donazette Street
Wellesley Massachusetts 02181(US)
Inventor: **Withy, Raymond M**
15 Millwood Circle
Framingham Massachusetts 01701(US)
Inventor: **Zabrecky, James R.**
36 Donna Road
Framingham Massachusetts 01701(US)
Inventor: **Masiello, Nicholas C.**
63 Pine Street
Milford Massachusetts 01757(US)

(74) Representative: **Sheard, Andrew Gregory et al**
Kilburn & Strobe 30, John Street
London WC1N 2DD(GB)

(54) **Recombinant human erythropoietin.**

(57) A rodent epithelioid cell transformed with a recombinant DNA vector including a DNA sequence encoding human erythropoietin is capable of producing N-linked and O-linked glycosylated human erythropoietin.

EP 0 267 678 A1

Recombinant Human Erythropoietin

This invention relates to the use of recombinant DNA techniques to produce human erythropoietin (EPO).

EPO is a protein, normally produced in the liver of the fetus and in the kidneys of adults, which plays a role in the regulation of the oxygen level of the blood by stimulating the proliferation and differentiation of red blood cell precursor cells to mature red blood cells. Purified EPO can be administered to human patients for the treatment of medical problems associated with inadequate red blood cell supply, e.g., anemia and chronic renal failure. EPO has been produced in cultured cells transformed with a vector containing a cDNA encoding EPO, e.g., as described in Kirin-Amgen PCT Application WO85/02610.

We have discovered that rodent epithelioid cells such as mouse C127 cells, when transformed with a recombinant DNA vector containing a DNA sequence encoding EPO, are capable of producing EPO of high biological activity which, like naturally-occurring EPO, is modified post-translationally by the addition of both N- and O-linked carbohydrates, which have attached a substantial amount of sialic acid, which is important in *in vivo* half-life. Presumably these post-translational modifications are enabled by the presence in the cells of the requisite enzymatic machinery.

We have found that the EPO produced by the recombinant cells of the invention have a different carbohydrate composition from urinary EPO, yet the recombinant EPO (rEPO) of the invention exhibits high biological activity.

Preferably, in the vector with which the cells are transformed, the EPO-encoding DNA sequence is under the transcriptional control of a eukaryotic metallothionein gene, and the vector further includes at least the 69% transforming region of the bovine papilloma virus genome (described in Howley et al., U.S. Pat. No. 4,419,446, hereby incorporated by reference).

The EPO of the invention exhibits good biological activity and is produced in high yield. In addition, the recombinant cells of the invention can be maintained in production in serum-free medium over a long period of time (at least 32 days). The use of serum-free media eliminates contamination of the final EPO product from non-EPO blood proteins, and greatly facilitates purification.

Accordingly, the invention also features a method of producing at least 99% pure EPO, involving a) culturing recombinant EPO-containing rodent epithelioid cells in nutrient medium free of serum to produce EPO-containing medium, b) clarifying the medium of cell debris to yield clarified EPO-containing medium, c) subjecting the EPO-containing medium to ion exchange chromatography to yield partially purified EPO, d) subjecting the partially purified EPO to reverse phase HPLC in an organic solvent to yield pure EPO in the organic solvent, and e) removing the organic solvent.

In preferred embodiments of the method, step (e) is carried out by ion exchange chromatography or by solvent evaporation or solvent removal by dialysis, followed by gel filtration.

In other preferred embodiments, following step (b), the clarified EPO-containing medium is treated to inhibit proteolytic degradation of EPO during step (c), by removal of proteases in the clarified EPO-containing medium by fractionation on a dye column, or by the addition of the clarified EPO-containing medium of a protease inhibitor.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiment thereof, and from the claims.

Description of the Preferred Embodiment

The drawings are first described.

Drawings

Fig. 1 is the nucleotide sequence of the coding region of human EPO (taken from Nature (1985), Vol. 313, p. 806) indicating the positions of two probes described herein ("EPO1" and "EPO2") which were used to isolate the gene; intron-exon junctions in the genomic clone are indicated by arrows.

Fig. 2 is a diagrammatic representation of the EPO gene in lamda EPO3, described herein; Fig. 2a gives confirmed restriction sites in lamda EPO3; Fig. 2b illustrates the sequencing strategy for the EPO coding regions. Black boxes denote EPO coding regions; solid arrows denote regions sequenced by the Maxam-Gilbert method, and broken lines denote regions subcloned into pUC18 and sequenced by the Sanger method. Restriction sites are: A = Aval; Bg = BgIII; Bs = BstEII; K = KpnI; P = PstI; Pv = Pvull; X = XbaI.

Fig. 3 is a set of diagrammatic illustrations of the EPO cDNA clones described herein, and the sequencing strategy employed. Broken arrows denote regions sequenced by the Sanger method, and solid arrows denote regions sequenced by the Maxam-Gilbert method. Restriction sites are: A = AccI; Bg = BgIII; H = HinfI; K = KpnI; P = PstI; X = XbaI.

Fig. 4 is a partial DNA sequence of EPO clones 104B and 125, described herein. Arrows denote intron-exon junctions. The XbaI and KpnI sites used in the construction of a full length EPO cDNA are shown.

Fig. 5 is a diagrammatic representation of the construction of a full length EPO cDNA clone and its insertion into BPV-based expression vectors. Restriction sites are B = BamHI; Bg = BgIII; K = KpnI; S = SalI; X = XbaI. The arrow denotes the MT promoter; filled-in boxes denote synthetic DNA; the botched box denotes EPO cDNA; double-hatched boxes denote MT non-promoter sequences; open boxes denote BPV sequences, lines indicate pBR322 sequences; and stippled boxes denote SV40 sequences.

Fig. 6 is a diagrammatic representation of the construction of EPO782 B/Bgl and EPO1789 B. Coding regions are shown as boxes, intron sequences as broken lines. Restriction sites are: B = BamHI; Bg = BgIII; K = KpnI.

Fig. 7 is a diagrammatic representation of the construction of an EPO genomic coding sequence suitable for insertion into BPV-based expression vectors. Boxes and restriction sites are as in Fig. 5, and Pu = Pvul.

Fig. 8a is a absorbance (280nm) profile of the n-propanol elution of EPO from a reverse phase C₈ column; the elution gradient was 0-40% n-propanol in 10Mm phosphate, pH 6.0. Fig. 8b shows SDS PAGE of fractions from the C₈ column; the fractions were analyzed with a 10% gel and stained with coomassie; fractions were pooled as indicated.

Fig. 9 is a graphical illustration of the stabilization of EPO at pH 5.0 by the protease inhibitor pepstatin.

Isolation of the human EPO gene

5 x 10⁵ plaques of a human genomic library (Lawn et al., 1978, Cell 15:1157) were screened by standard techniques with two synthetic DNA probes (EPO1 and EPO2, see Fig. 1) that correspond to portions of the published EPO DNA sequence (Jacobs et al., 1985, Nature, 313:806). One clone that hybridized to both probes (lambda EPO3) was analyzed by restriction mapping and shown to contain the entire EPO gene on a 20kb EcoRI fragment (see Fig. 2). The exons of the EPO gene were sequenced and found to be identical to the published DNA sequence.

Isolation of human EPO cDNA clones

A cDNA library was constructed from mRNA isolated from a human fetus of about 20 weeks gestation by the insertion of dG-tailed cDNA into the dG-tailed plasmid vector pKT218 by standard cloning procedures. The library, consisting of about 140,000 clones, was screened with the synthetic DNA probes EPO1 and EPO2. Four positive clones were found.

Clone 104B, which hybridized to probes EPO1 and EPO2 and clone 125 that hybridized to the 5' probe EPO1 only were analyzed further. Clones 104B (1330bp long) and 125 (810bp long) and the sequencing strategy are shown in Fig. 3. Partial DNA sequences of these clones are given in Fig. 4.

The sequence of clone 104B between nucleotides 63 and 724 has 100% homology with the published DNA sequence of the EPO cDNA. This clone thus contains the entire coding sequence for the 166 amino acids of the mature EPO protein and for 22 amino acids of the leader sequence. The first 13 nucleotides of the coding region are missing in this clone, and are replaced by 62 nucleotides that originate from the intron between exons 1 and 2 of the EPO gene. The RNA from which this sequence was derived probably resulted from an aberrant splicing event.

A comparison of the sequence of clone 125 with the published EPO sequence showed that this clone

codes for amino acids -22 to +55 of the EPO protein. At the 5' end of this clone are 72 nucleotides of the intron between exons 1 and 2 (only 27 nucleotides are shown in Fig. 4) and at the 3' end are approximately 460 nucleotides of the intron between exons 3 and 4 (only the first 64 nucleotides of this intron were sequenced). The intron between exons 2 and 3 has been spliced out correctly.

Construction of a full length EPO cDNA clone and its insertion into mammalian expression vectors

Since none of the cDNA clones contains the complete EPO coding region, the 13 nucleotides of the first exon of EPO that code for the amino terminus of the leader peptide were synthesized. Due to the aberrant splicing in clone 104B, there was no convenient restriction site available in this clone that could be used to attach the synthetic DNA coding for the first exon. In clone 125, on the other hand, there is an XbaI site just 5' of the second exon that could be used for a fusion of the synthetic DNA to the second exon. A full length cDNA could then be constructed by combining this exon 1-2 fusion in clone 125 with the 3' fragment of the cDNA of clone 104B at the common KpnI site. A detailed description of this construction is given below and is illustrated in Figs. 5 and 6.

EPO125 was digested with XbaI, leaving a 4bp 5' overhang at the 5' end of exon 2. This single-stranded overhang was removed using exonuclease S1 to give blunt ends that start exactly at the second exon of EPO. To those ends, the following synthetic DNA fragments were ligated on:

```

          BamHI      EcoRI      -27      -24
VV173:  5'  G A T C C G A A T T C A T G G G G G T G C A C G  3'
VV172:          3'  G C T T A A G T A C C C C C A C G T G C  5'

```

These linkers contain a BamHI overhang at the 5' end for insertion into BPV based expression vectors (see below) followed by an EcoRI site for insertion into SV40 vectors, as well as the 13 nucleotide coding region of the first exon of the EPO gene. In order to avoid self-ligation of these linkers at the BamHI overhangs, only VV172 was kinased. After addition of the linkers, EPO 125 was digested with KpnI, and the 137bp BamHI-KpnI fragment was isolated and ligated into BamHI plus KpnI cut pUC18 to yield pUCEPO.

Four single clones of this construction were sequenced and found to have the expected sequence with the correct fusion of the synthetic DNA and the second exon at the modified XbaI site. The 137bp BamHI-KpnI fragment of pUCEPO coding for the 5' portion of EPO and the 649bp KpnI-BglII fragment of EPO 104B coding for the 3' portion of EPO were isolated and ligated into the alkaline phosphatase treated BglII site of vectors CL28Bam and CLH3a, respectively (see below). The 5' to 3' orientation of the EPO cDNA insert within the vectors was checked by restriction mapping. The resulting plasmids, EPO782 B/Bgl Mt and EPO782 B/Bgl SV were digested with BamHI and Sall and the BPV genome (publicly available; see Howley et al., id) was inserted as a BamHI-Sall fragment to yield the expression plasmids EPO782 Mt BPV and EPO782 SV BPV. Construction of a modified EPO gene suitable for insertion into mammalian expression vectors

Because of the high incidence of cDNA clones isolated that have incompletely removed the first intron of the EPO gene (see above and also Jacobs et al., id.), a modified EPO genomic clone was constructed from which the first intron had been removed by genetic engineering. This could be conveniently carried out by combining the 5' portion of the cDNA clone EPO782 B/Bgl with the 3' sequences of the EPO gene at the single KpnI site which is located in the second exon of the gene. This construction is described in detail below and illustrated in Figs. 6 and 7.

The 1763bp long XbaI-BglII fragment of lambda EPO3 (see Fig. 2), containing all but the first exon of EPO, was subcloned into T25B, a vector containing single XbaI and BglII sites to yield plasmids T25Xba/Bgl (see Fig. 7).

T25Xba/Bgl was digested with BglII, the overhangs were filled in using the Klenow fragment of DNA polymerase, BamHI linkers were added, and the vector was circularized. The 2.3kb KpnI fragment of T25Xba/B containing the 3' portion of the EPO gene and some metallothionein sequences was then ligated into KpnI-cut pUC EPO (see Fig. 5) to give EPO1789B. This plasmid contains the desired EPO gene from which the first intron has been removed. The EPO-containing BamHI fragment from EPO1789B was isolated and ligated into the BglII site of CLH3a to yield plasmid EPO1789BPV. The 5' to 3' orientation of the EPO clone within the vector was checked by restriction analysis. Into this plasmid was inserted the BPV genome as a BamHI-Sall fragment to yield expression plasmid EPO1789SVBPV.

Expression vectors and transfection of mammalian epithelioid cells

The EPO cDNA and the modified genomic clone can be inserted into any suitable mammalian expression vector, most preferably those that can be used to transform rodent epithelioid cells such as mouse C127 cells. Preferred expression vectors are the BPV vectors described in Wei et al., U.S.S.N. 782,686, filed October 1, 1985, assigned to the same assignee as the present invention and hereby incorporated by reference, and Hsiung et al., 1984, J. Molec. and App. Genet, 2:497. The vectors (Figs. 5 and 7) include a mouse metallothionein promoter (MT) from which inserted genes can be transcribed, and bovine papilloma virus DNA (BPV) to effect transfection of mammalian cells. The vector CLH3a also includes late promoter poly-adenylation sequences derived from SV40 virus, which can effect expression from a gene inserted into the vector. The illustrated expression plasmids also include a portion of the *E. coli* plasmid pML, which permits shuttling between prokaryotic and eukaryotic systems. No selection is required for the maintenance of these plasmids in host cells, and they are maintained in high copy number (approximately 50-100 copies/cell). The EPO cDNA and the modified EPO genomic clone were inserted into these BPV vectors as described above. The final expression vector constructs are shown in Figs. 5 and 7. As a matter of convenience, the names of the expression vectors have been shortened to CEM, CES and CEG for EPO782MtBPV, EPO782SVBPV, and EPO1789SVBPV, respectively. These vectors were transformed into *E. coli* strain MC1061 using conventional methods and grown in bulk culture. The DNAs were purified by CsCl banding before transfection into mammalian cells.

On separate days, three to five sets of transfections with the different vectors into mouse C127 cells (commercially available) were carried out as follows:

Mouse C127 cells were maintained in Dulbecco's modified Eagle's medium (DME) supplemented with 10% fetal calf serum and 10mM glutamine as described in Hsiung et al., *id.* DNA transfections were carried out by the method described in Wilger et al. 1977, Cell 11:233, as modified by Hsiung et al., *id.* Ten to twenty micrograms of calcium phosphate precipitated DNA was incubated for six to eight hours at 37°C with 1×10^6 cells in fresh culture medium. The medium was removed and the cells treated with 20% glycerol in 10mM phosphate-buffered saline (PBS), pH7.0, for one to two minutes at room temperature, washed twice with PBS and fresh DME added. The cells were then incubated at 37°C and the medium replaced after 24 hours and every three to four days thereafter.

EPO expression

Foci, representing BPV transformed C127 cells, were detectable 10-14 days after transfection. Supernatants from plates containing transformants were assayed 17 days after transfection by the ³H-thy uptake assay (Krystal 1983, Exp. Hematol., 11/7, 649) and found to contain EPO. 2 1/2 to 3 weeks after transfection, foci were isolated by the cloning ring method and transferred to T-25 flasks. After the cells reached approximately 20% confluency, the supernatants were tested for EPO production by the ³H-thy uptake assay. A total of 76 cell lines (15 CEM, 35 CES and 26 CEG transformants) were transferred into T-75 flasks.

When the cells were confluent, the supernatants were assayed for EPO expression and the cells were counted and frozen. To test the reproducibility and stability of these cell lines, the 21 highest producing cell lines were thawed and rescreened for 24 hours expression levels on a per cell basis. The five highest producers (3CES and 2CEG transformants) were chosen and expanded into roller bottles to test for growth and production properties. Representative 24 hour culture fluids from cell lines CES9dog and CEG4d in T-75 flasks contained 600U/ml and 800U/ml of rEPO as measured by the ³H-thy uptake assay using human urinary EPO as a standard and 490 and 540U/ml when measured by the ⁵⁹Fe incorporation assay into rat bone marrow cells *in vitro* (Goldwasser et al., 1975, Endocrinology 97:315.). These samples were also active *in vivo* in the polycythemic mouse assay as described by Cotes et al., 1961, Nature 191:1085.

Production of recombinant human EPO

Production of EPO from transformed C127 cells in serum-free medium was achieved by expanding the cells in serum containing medium in roller bottles, transferring the cells onto microcarrier beads in spinner culture vessels, and replacing the serum-containing growth medium with serum-free production medium once the cells had reached saturation density. The conditioned culture medium was then regularly replaced with fresh serum-free medium and the vessels kept in a continuous production for months without the

addition of any serum. This method allows economical production of large quantities of serum-free conditioned medium from which recombinant human EPO can readily be purified (see below).

Cells from cell line CES9dog are grown in roller bottles containing DME + 10% FBS under standard culture conditions. The procedure for the preparation and inoculation of microcarrier spinner cultures is similar for all vessel sizes ranging from 100ml to 15L. All microcarrier spinners are provided by the Belco Glass Company. Before each use, the individual spinners are freshly washed, air dried and then have a thin coating of silicone (Sigmacote, Sigma Chemical Co.) applied to the interior glass surface. After drying, the vessels are extensively rinsed with distilled water before use.

The microcarrier beads of choice for production of EPO are Cytodex 3 (Pharmacia). Final microcarrier concentration in all suspension vessels is 5gm/liter of culture media. The vessel is filled with one-half of its final working volume with PBS and the appropriate amount of dry microcarrier beads are added. The beads are allowed to swell for three hours at room temperature. They are then rinsed twice with PBS by decanting and the vessel volume returned to one-half of its working volume. The vessel is loosely capped, prepared for autoclaving and then steam sterilized for one hour at 121°C (two hours for the 15L vessels). After cooling to room temperature the PBS is withdrawn to 20% of final working volume and DMEM is added to the final volume. The culture is then stirred for 30 minutes at 37°C. After stirring, the beads are allowed to settle and 80% of the supernatant is replaced with fresh growth media with 10% FBS. The vessels are now ready for inoculation.

As an example, two 15 liter spinner flasks were seeded with cells from the CES9dog line. Each spinner was seeded with freshly trypsinized cells from 15 roller bottles in 10 liters of growth medium (DMEM + 10% FBS) and 5g/liter of Cytodex 3 beads. The initial concentration of cells in the vessels was 1×10^5 cells/ml. The cultures were then placed on magnetic stirrers (Belco) and grown at 37°C. The 10 liter spinners were stirred at 20rpm. The cultures were sampled daily and on day two, 80% of the growth medium was replaced with fresh medium. At this point, the overlayer aeration was started by flushing the head space with a mixture of 95% air/5% CO₂. On day four, the growth medium was replaced again. On day six the cell numbers were between 1.75 and 2.5×10^6 cells/ml. Cells were enumerated by counting nuclei (Levine et al., Somatic Cell Genetics (1977) 3:149).

At this point, the spinner cultures were transferred to the production phase: the growth medium was exchanged twice (80% volume exchange each time) with DMEM without serum and after the second rinse, the medium was replaced with CEM2000 without serum (Scott Labs). The cultures were sampled every day for EPO production. Every 48 hours 80% of the conditioned medium was collected and replaced with an equal volume of fresh CEM2000 (eight liters per spinner). The medium from both vessels were pooled on each collection day and submitted for purification. Representative serum-free media harvested from 10L spinner cultures (described above) contained human EPO at a concentration of approximately 600U/ml as judged by the ³H-thy incorporation assay and an EPO radioimmunoassay using human urinary EPO as a standard.

As another example, six one liter spinner flasks were seeded with CES9dog cells in DMEM + 10% FBS. After the cells had reached saturation density, the vessels were put into production by replacement of 80% of the growth medium with serum-free production medium as described above. The media from duplicate vessels were harvested every 48, 72 or 96 hours, respectively. The average EPO production in these one liter spinners was 576, 698 and 842 units per 24 hours as measured by RIA for the 48, 72 and 96 hour harvest schedules, respectively. At 32 days, the cells were still producing EPO at the same levels.

45 Purification of recombinant EPO

Recombinant human EPO can readily be purified from serum-free medium conditioned by mammalian cells producing rEPO. The purification to homogeneity generally involves the steps of: (1) clarification, concentration and dialysis of culture medium; (2) ion-exchange chromatography; (3) reverse phase high performance liquid chromatography (RP-HPLC); and (4) gel filtration or ion exchange chromatography. Steps 1 and 2 will remove from the culture medium proteases and some serum components remaining in the production medium (specifically in harvests shortly after switching the cultures from serum containing growth into serum-free production medium); steps 2 and 3 give a major purification, and step 4 is designed to remove the organic solvent used in step 3 and to elute the purified EPO in the final formulation buffer. These steps are described in more detail below. All purification procedures are carried out at 4°C with the exception of the RP-HPLC step, which is carried out at room temperature.

As an example, pure, homogenous rEPO was prepared from 11.75 liters of serum-free EPO production medium harvested from the 10 liter spinner cultures described above. EPO levels were measured throughout the purification process using the ^3H -thy incorporation assay and an EPO RIA. All dose response curves at the different purification stages were parallel to each other and to the human urinary standard.

1) Clarification, concentration and dialysis of culture medium

11.75 liters of CES9dog conditioned serum-free media, harvested from 10 liter spinner flasks and containing approximately 700 units of EPO per ml, were made 0.01% in Tween 80, and then clarified of cell debris and microcarriers by passage through a 0.5 μm Pall ProfileTM filter cartridge at a flow rate of 2.5L/minute. The pressure of the cartridge did not exceed 20psi. The clarified media were then concentrated 10-fold and flow dialyzed into 50mM Na Acetate, pH5.0 containing 15mM NaCl, and 0.01% Tween 80 to a final conductivity of 6.90mS/cm². This was accomplished with a tangential flow system: an Amicon Spiral Ultrafiltration S10Y10 cartridge having a YM 10,000 MW cutoff membrane was used at a retention flow rate of 1.5-2L/minute, a breakthrough flow rate of 0.4-0.8L/minute, and a back pressure maintained at 25-30psi. The volume of the final concentrate was 970ml, its pH was 5.0, and its conductivity 6.90mS/cm². EPO recovery through these steps is greater than 90%.

2) Ion exchange chromatography

A screen of ion exchange resins demonstrated that relatively high ionic strength resins are best suited for the purification of EPO. In this particular example, an S-Sepharose Fast Flow column from Pharmacia was used. A 2.5cm x 12.5cm (60ml) column was equilibrated at 4°C with 50mM Na Acetate, pH5.0, containing 15mM NaCl, and having a conductivity of 6.90mS/cm². The absorbance of the column effluent was monitored at 280nm with an in-line detector (LKB). The column was loaded with 960ml of the concentrated media at a flow rate of 5ml/minute (61.6cm/hour) and the column was washed with equilibration buffer until the absorbance returned to baseline (approximately 2 column volumes). The column was eluted with a 300ml linear salt gradient of 0.015M to 0.4M NaCl in 50mM Na Acetate, pH5.0. Fractions (6ml) were collected into tubes containing 0.15ml of 2M Tris-HCl, pH8.8. This adjusted the pH of the effluent to approximately 8.0 and gave a final Tris concentration of 0.05M. Finally, the column was washed with 0.05M Tris-HCl, pH9.0, containing 2M NaCl. EPO-containing fractions were pooled.

The S-Sepharose Fast Flow column gave an approximately 7-fold purification and a recovery of about 60%. Losses at this step are due to proteases present in the conditioned medium which are active at pH5.0 (which is the optimal pH for EPO purification with this resin). (As is described below, losses at this step can be minimized by the use of immobilized dyes or protease inhibitors.)

3) Preparative Reverse Phase HPLC

HPLC was carried out with a Waters high pressure liquid chromatography system consisting of a model 6000A solvent delivery system and a model 660 solvent programmer. A 2.2cm x 25cm preparative C₈ column (Amicon 10 μm particle size, 100A pore size) was equilibrated at room temperature with 10mM NaPO₄, pH6.0 buffer. (A column of different carbon length, e.g., C₄-C₁₈, can also be used, but are less preferred.). The pooled S-Sepharose sample was prefiltered through a 0.45 μm Gelman Acrodisk filter and loaded onto the column by repeated injections using a 2ml sample loop. The column was run at 6ml/minute (71.0cm/h) and the absorbance of the effluent was monitored at 280nm. Following loading the sample, the column was washed with 10mM NaPO₄, pH6.0, until the absorbance returned to baseline. The column was eluted with a 2.5h linear 0% to 40% n-propanol gradient (in 10mM NaPO₄, pH6). One minute fractions (6ml) were collected.

Several small peaks of material absorbing at 280nm were eluted between 60 minutes and 95 minutes of the gradient and a single, sharp peak eluted between 100 minutes to 110 minutes (Fig. 8). The elution peaks were analyzed by SDS PAGE. The EPO containing fractions coincided with the large peak at 100 minutes to 107 minutes (approximately 25% propanol). A laser densitometer scan of the coomassie stained

SDS gel indicated that the EPO was greater than 99% pure at this stage. In this example, the C₈ step gave a 2-fold purification.

The recovery of immunological and of *in vitro* biological activity at this step was high (83%), indicating that n-propanol had no adverse effects on the *in vitro* biological activity.

5

4) Gel filtration chromatography

To ensure complete removal of the organic solvent and to elute the purified EPO in a desired physiologically compatible buffer, the C₈-purified material can be further fractionated by gel filtration chromatography. If the gel filtration resin is not compatible with high concentrations of organic solvents, a flow-dialysis step must be used prior to gel filtration in order to remove the majority of the organic solvent. If the resin matrix of the last column is resistant to the organic solvent used, the pooled fractions from the RP-HPLC step can be passed directly over this column under conditions where the protein binds to the resin and the organic solvent flows through. The organic solvent can then be washed out extensively with a
15 aqueous buffer and the protein can finally be eluted from the column.

The elution pool from the C₈ column was made 1% mannitol and 0.5M NaCl by the addition of solid material, and then introduced into an Amicon stir cell having a YM10 (10,000 M.W. cutoff) ultrafiltration membrane. The volume was reduced approximately ten fold and then restored to the original volume with
20 15mM NaPO₄, pH7.2, containing 0.5M NaCl and 1% mannitol. The process was repeated twice and the dialyzed pool was concentrated to a final volume of 17.5ml. Analysis of this process for total protein using the Lowry method showed greater than 98% recovery. Fourteen ml of the dialyzed material was then fractionated by gel filtration chromatography.

A 2.5cm x 98cm (481ml) column of GC200 Cellufine filtration resin (Amicon) was equilibrated at 4°C
25 with 15mM NaPO₄, pH7.2 buffer containing 0.5M NaCl and 1% mannitol at a flow rate of 0.8ml/minute (9.8cm/hour). The 14ml sample was loaded, the column effluent was monitored at 280nm, and 6ml fractions were collected. A single, symmetrical peak was eluted and SDS PAGE confirmed the peak to be EPO. No further purification of EPO was achieved at this step and the recovery was 89%.

EPO produced by the above purification method was shown to be greater than 99% pure as judged by
30 SDS-PAGE and to have high potency in *in vitro* and *in vivo* biological assays. The overall EPO yield in this example was 41%.

The addition of a dye column to step 1 gives some additional purification and, more importantly, removes contaminating proteases from EPO and consequently allows higher EPO recoveries at the S-Sepharose Fast Flow step. The clarified media was loaded on a Blue Trisacryl-M column (Pharmacia)
35 equilibrated with 10mM NaPO₄ pH6.0, 150mM NaCl and eluted with a linear salt gradient of 0.15 to 2.5M NaCl in 10mM NaPO₄ pH6.0 and then flow-dialyzed into 50mM Na Acetate, pH5.0 containing 15mM NaCl. The recovery of EPO from the Blue Trisacryl column was almost complete and the recovery on the following S-Sepharose Fast Flow column was 86% compared to 60% in example 1. EPO containing 10X concentrated medium or partially purified step 2 material has been shown to degrade rapidly (t_{1/2} approx.
40 4h) when incubated at 37°C under mildly acidic conditions at pH5.0. This degradation seems to be caused by proteases that are active at pH5.0. The improved yields in step 2 as illustrated in this example can be attributed to the separation of proteases from the EPO protein by the Blue Trisacryl column. (Other commercially available dyes can also be used.)

Protease inhibitors can also be added to the conditioned medium in order to improve EPO yields.
45 Several commercially available protease inhibitors were tested to see if they could prevent EPO degradation at pH5.0. 10X concentrated (Step 1) EPO medium was diluted 1:10 in 50mM Na Acetate, pH5.0 and then incubated at 37°C with or without protease inhibitors at a concentration of 5 micrograms/ml. Aliquots were taken over a period of 29 hours and assayed by RIA. This experiment showed that pepstatin (Sigma) had a significant stabilizing effect on EPO immunoactivity over this time period at pH5.0. Pepstatin was then
50 tested to determine the minimum concentration at which it is effective. Under the same conditions as described above, pepstatin was included into 10X concentrated medium over range of 0.0005 to 1ug/ml and incubated at 37°C for 25 hours. The IC₅₀ (the concentration at which 50% of the proteases are inhibited) of pepstatin is approximately 0.02ug/ml (Fig. 9). To test the effect of pepstatin in the purification process, 0.2ug/ml of pepstatin was added to the 10X concentrated medium and to the buffers for the S-Sepharose
55 column. Under these conditions, 97% of EPO was recovered from the S-Sepharose Fast Flow column compared to approximately 60% without the use of a protease inhibitor.

The gel filtration chromatography step (Step 4, above) can be replaced by an S-Sepharose Fast Flow ion exchange step to remove organic solvents. Fractions containing EPO eluted from the C₈ column at

approximately 25% propanol were pooled, the pH was lowered to 5.0 by dilution with nine volumes of 0.05M Na Acetate buffer, pH5.0 and then applied to a S-Sepharose Fast Flow column equilibrated in 50mM Na Acetate pH5.0 containing 15mM NaCl. The column was washed with several volumes of this buffer and EPO was then eluted with PBS pH8.0. EPO recovery at this step was quantitative and the final product was found to be free of residual propanol.

Characterization of the purified rEPO

rEPO purified from medium conditioned by CES9dog cells as described above was partially characterized and compared to human urinary EPO. Analysis of the rEPO by SDS-PAGE followed by coomassie blue and silver staining showed that rEPO purified by this method was greater than 99% pure. It migrates with an apparent molecular weight of approximately 34K on SDS-PAGE as a single protein band.

The amino acid sequence of purified rEPO was determined by both N-terminal sequencing and enzymatic digestion of the rEPO, separation of the created peptides by reverse phase HPLC and sequencing of these peptides using a gas phase sequencer. More than 95% of the EPO molecule has been sequenced. The following observations have been made: the amino acid sequence of rEPO produced by BPV transformed C127 cells is indistinguishable from that of human urinary EPO. In particular, the amino-terminal sequence analysis indicated that the hydrophobic leader peptide is cleaved at the correct position. No signal for any PTH (Phenyl-thiohydantoins) amino acid was observed at positions 24, 38 and 83 of the EPO peptide. These positions correspond to Asn in the EPO sequence, which represent possible sites for the addition of N-linked carbohydrates (Asn-X-Ser or Thr, Neuberger et al., 1972: The Glycoproteins: Their Composition, Structure and Function, p. 450). This data and the results of carbohydrate analysis of EPO strongly suggests that in rEPO produced in C127 cells all three possible N-glycosylation sites are indeed glycosylated. Amino acid position 126 corresponds to a serine in the nucleic acid sequence. No signal for any PTH amino acid was seen at this position. Carbohydrate analysis of a peptide containing this residue indicated the presence of galactose, indicating that Ser126 is O-link glycosylated. Carbohydrate analysis of rEPO revealed the presence of both neutral and amino sugars and substantial amounts of galactose and sialic acid. The carbohydrate composition of EPO of the invention differs from the published carbohydrate composition of human urinary EPO. (We have not independently analyzed urinary EPO, and therefore cannot be certain the published results are accurate.) The rEPO of the invention was determined to have high biological activity in in vitro and in vivo assays.

Therapeutic Use

Human EPO can be lyophilized and reconstituted in steric water prior to use. EPO in saline can be administered on a regular basis (e.g., weekly) to human patients suffering from anemia or renal failure. Administration is by the modes of administration used for other blood affecting proteins, e.g., tissue plasminogen activator. Most preferably, administration is by bolus injection or by intravenous infusion.

For long-term maintenance of a human patient, for example, 10-100 µg of lyophilized EPO are dissolved in sterile water and placed in the chamber of a syringe, which is used to inject a bolus of EPO into the patient intravenously; treatment is carried out three times per week.

Diagnostic use

Antibodies, either polyclonal or monoclonal, can be raised to EPO and used in conventional immunoassay methods to quantify EPO in biological fluids, e.g., serum or urine, of patients suspected of being deficient in EPO.

Deposits

E. coli cells containing the plasmid CES were deposited on September 12, 1986, with the Agricultural Research Culture Collection, and assigned NRRL Accession Number B-18113.

Other embodiments are within the following claims. For example, although the use of all of the BPV genome is preferred, just the 69% transforming region can also be used. However, when only the 69%

region is used, there might be undesirable interactions between the plasmid and the chromosome of the host cell, i.e., much of the plasmid DNA can incorporate into the chromosome rather than remaining episomal, so that the plasmid is more difficult to retrieve from the cells. Also, if less than the entire BPV genome is used, the pBR region which is frequently attached to BPV (since BPV is normally provided as part of a pBR322-derived plasmid), must be removed prior to transfection, because the pBR region, in a less than complete BPV fragment, can have an inhibitory effect on transfection. This does not occur when using full length BPV DNA. Undesirable rearrangements might also occur when using only the 69% region.

It is preferable that the eukaryotic metallothionein promoter be of mammalian, most preferably murine, origin, but any suitable metallothionein promoter can be used (each mammalian species which produces a metallothionein apparently does so using a structurally different gene).

To construct a vector within the invention, other than CES, cell line DNA can be used as the source of the MT promoter and structural gene, the EPO gene, and the BPV genome, and those genetic elements can be inserted, using conventional recombinant DNA techniques, into a desired vector.

Any suitable host cells can be used. For example, other rodent fibroblast cell lines which can be infected by BPV can be used; for example, NIH 3T3 cells (ATCC CCL 92) can be used.

Claims

1. A rodent epithelioid cell transformed with a recombinant DNA vector comprising a DNA sequence encoding human erythropoietin, said transformed cell being capable of producing N-linked and O-linked glycosylated human erythropoietin.
2. A cell as claimed in claim 1 wherein said DNA sequence encoding human erythropoietin is under the transcriptional control of a promoter for a eukaryotic metallothionein gene.
3. A cell as claimed in claim 1 or 2 wherein said vector further comprises at least the 69% transforming region of the bovine papilloma virus genome.
4. A cell as claimed in claim 1, said cell being a mouse C127 cell.
5. Human erythropoietin produced by a cell as claimed in any use of claims 1 to 4.
6. Erythropoietin as claimed in claim 5 wherein said erythropoietin has a different carbohydrate composition from urinary EPO.
7. A method of producing at least 99% pure erythropoietin (EPO), said method comprising
 - a) culturing recombinant EPO-containing rodent epithelioid cells in nutrient medium free of serum to produce EPO-containing medium,
 - b) clarifying said medium of cell debris to yield clarified EPO-containing medium,
 - c) subjecting said EPO-containing medium to ion exchange chromatography to yield partially purified EPO.
 - d) subjecting said partially purified EPO to reverse phase HPLC in an organic solvent to yield pure EPO in said organic solvent, and
 - e) removing said organic solvent.
8. A method as claimed in claim 7 wherein said step (e) is carried out by (i) ion exchange chromatography, and/or (ii) solvent evaporation or removal by dialysis, followed by gel filtration.
9. A method as claimed in claim 7 or 8 wherein, following said step (b), said clarified EPO-containing medium is treated to inhibit proteolytic degradation of said EPO during said step (c).
10. A method as claimed in claim 10 wherein said treatment to inhibit proteolytic cleavage comprises
 - (i) removal of proteases in said clarified EPO-containing medium by fractionation on a dye column, and/or
 - (ii) addition to said clarified EPO-containing medium of a protease inhibitor.
11. A method as claimed in any one of claims 7 to 10, wherein said reverse phase HPLC of step (d) is carried out using a C8 column.

FOR THE FOLLOWING CONTRACTING STATES: AT AND ES

1. A process for producing a transformed rodent epithelioid cell, the process comprising transforming a rodent epithelioid cell with a recombinant DNA vector comprising a DNA sequence encoding human erythropoietin to produce a cell which is capable of producing N-linked and O-linked glycosylated human erythropoietin.

2. A process as claimed in claim 1 wherein said DNA sequence encoding human erythropoietin is under the transcriptional control of a promoter for a eukaryotic metallothionein gene.

3. A process as claimed in claim 1 or 2, wherein said vector further comprises at least the 69% transforming region of the bovine papilloma virus genome.
4. A process as claimed in claim 1, said cell being a mouse C127 cell.
5. A process for the preparation of human erythropoietin, the process comprising culturing a rodent epithelioid cell transformed with a recombinant DNA vector comprising a DNA sequence encoding human erythropoietin, said transformed cell being capable of producing N-linked and O-linked glycosylated human erythropoietin.
6. A process as claimed in claim 5 wherein said erythropoietin has a different carbohydrate composition from urinary EPO.
- 10 7. A method of producing at least 99% pure erythropoietin (EPO), said method comprising
 - a) culturing recombinant EPO-containing rodent epithelioid cells in nutrient medium free of serum to
 - 25 produce EPO-containing medium,
 - b) clarifying said medium of cell debris to yield clarified EPO-containing medium,
 - c) subjecting said EPO-containing medium to ion exchange chromatography to yield partially purified
 - 15 EPO.
 - d) subjecting said partially purified EPO to reverse phase HPLC in an organic solvent to yield pure EPO in said organic solvent, and
 - e) removing said organic solvent.
8. A method as claimed in claim 7 wherein said step (e) is carried out by (i) ion exchange chromatography, and/or (ii) solvent evaporation or removal by dialysis, followed by gel filtration.
- 20 9. A method as claimed in claim 7 or 8 wherein, following said step (b), said clarified EPO-containing medium is treated to inhibit proteolytic degradation of said EPO during said step (c).
10. A method as claimed in claim 10 wherein said treatment to inhibit proteolytic cleavage comprises
 - (i) removal of proteases in said clarified EPO-containing medium by fractionation on a dye column, and/or
 - 25 (ii) addition to said clarified EPO-containing medium of a protease inhibitor.
11. A method as claimed in any one of claims 7 to 10, wherein said reverse phase HPLC of step (d) is carried out using a C8 column.

30 FOR THE FOLLOWING CONTRACTING STATE: GR

1. A rodent epithelioid cell transformed with a recombinant DNA vector comprising a DNA sequence encoding human erythropoietin, said transformed cell being capable of producing N-linked and O-linked glycosylated human erythropoietin.
- 35 2. A cell as claimed in claim 1 wherein said DNA sequence encoding human erythropoietin is under the transcriptional control of a promoter for a eukaryotic metallothionein gene.
3. A cell as claimed in claim 1 or 2 wherein said vector further comprises at least the 69% transforming region of the bovine papilloma virus genome.
4. A cell as claimed in claim 1, said cell being a mouse C127 cell.
- 40 5. A process for the preparation of human erythropoietin, the process comprising culturing a rodent epithelioid cell transformed with a recombinant DNA vector comprising a DNA sequence encoding human erythropoietin, said transformed cell being capable of producing N-linked and O-linked glycosylated human erythropoietin.
6. A process as claimed in claim 5 wherein said erythropoietin has a different carbohydrate composition
- 45 from urinary EPO.
7. A method of producing at least 99% pure erythropoietin (EPO), said method comprising
 - a) culturing recombinant EPO-containing rodent epithelioid cells in nutrient medium free of serum to
 - 25 produce EPO-containing medium,
 - b) clarifying said medium of cell debris to yield clarified EPO-containing medium,
 - 50 c) subjecting said EPO-containing medium to ion exchange chromatography to yield partially purified EPO.
 - d) subjecting said partially purified EPO to reverse phase HPLC in an organic solvent to yield pure EPO in said organic solvent, and
 - e) removing said organic solvent.
- 55 8. A method as claimed in claim 7 wherein said step (e) is carried out by (i) ion exchange chromatography, and/or (ii) solvent evaporation or removal by dialysis, followed by gel filtration.
9. A method as claimed in claim 7 or 8 wherein, following said step (b), said clarified EPO-containing medium is treated to inhibit proteolytic degradation of said EPO during said step (c).

10. A method as claimed in claim 10 wherein said treatment to inhibit proteolytic cleavage comprises
(i) removal of proteases in said clarified EPO-containing medium by fractionation on a dye column, and/or
(ii) addition to said clarified EPO-containing medium of a protease inhibitor.

11. A method as claimed in any one of claims 7 to 10, wherein said reverse phase HPLC to step (d) is
5 carried out using a C8 column.

10

15

20

25

30

35

40

45

50

55

| | | | | | |
|---|---|------|-----|------|-----|
| -23 | -27 | -20 | 30 | -10 | 60 |
| ATG GGG GTG CAC GAA | TGT CCT GCC TGG CTG TGG CTT CTC CTG TCC CTG CTG TCG CTC CCT | | | | |
| Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Ser Leu Ser Leu Pro | | | | | |
| | | +1 | 90 | +10 | 120 |
| CTG GGC CTC CCA CTC CTG GGC GCC CCA CCA CGC CTC ATC TGT GAC AGC CGA GTC CTG GAG | | | | | |
| Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu | | | | | |
| | | | | | |
| | | +20 | 150 | +26 | +27 |
| AGG TAC CTC TTG GAG GCC AAG GAG GCC GAG AAT ATC ACG ACG GGC TGT GCT GAA CAC TGC | | | | | |
| Arg Tyr Leu Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr | | | | | |
| | | | | | |
| | | +40 | 210 | +50 | 240 |
| AGC TTG AAT GAG AAT ATC ACT GTC | CCA GAC ACC AAA GTT AAT TTC TAT GCC TGG AAG AGG | | | | |
| Ser Leu Asn Glu Asn Ile Thr Val | Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg | | | | |
| | | | | | |
| +55 | +56 | +60 | 270 | +70 | 300 |
| ATG GAG GTC GGG CAG CAG GCC GRA GAA GTC TGG CAG GGC CTG GCC CTG TCG GAA GCT | | | | | |
| Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Leu Ser Glu Ala | | | | | |
| | | | | | |
| | | +80 | 330 | +90 | 360 |
| GTC CTG CGG GGC CAG GCC CTG TTG GTC AAC TCT TCC CAG CCG TGG GAG CCC CTG CAG CTG | | | | | |
| Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu | | | | | |
| | | | | | |
| | | +100 | 390 | +110 | 420 |
| CAT GTG GAT AAA GCC GTC AGT GGC CTT CGC AGC CTC ACC ACT CTG CTT CGG GCT CTG GGA | | | | | |
| His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly | | | | | |
| | | | | | |
| +115 | +116 | +120 | 450 | 130 | 480 |
| GCC CAG AAG GAA GCC ATC TCC CCT CCA GAT GCG GCC TCA GCT GCT CCA CTC CGA ACA ATC | | | | | |
| Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile | | | | | |
| | | | | | |
| | | +140 | 510 | +150 | 540 |
| ACT GCT GAC ACT TTC CGC AAA CTC TTC CGA GTC TAC TCC AAT TTC CTC CGG GGA AAG CTG | | | | | |
| Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu | | | | | |
| | | | | | |
| | | +160 | 570 | +166 | |
| AAG CTG TAC ACA GGG GAG GCC TGC AGG ACA GGG GAC AGA TGA | | | | | |
| Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg End | | | | | |

FIG. 1




FIG. 2a




FIG. 2b





FIG. 3

EPO 140B

31 61
 T CTG CCA GAG GGG AAG CCT CTG TCA CAC CAG GAT TGA AGT TTG GCC GGA GAA GTG GAT GCT
 -22 91 121
 ▼ GAA TGT CCT GCC TGG CTG TGC CTT CTC CTG TCC CTG CTG TCG CTC CCT CTG GGC CTC CCA
 Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu Leu Ser Leu Pro Leu Gly Leu Pro
 +1 151 KpnI 181
 GTC CTG GGC GCC CCA CCA CGC CTC ATC TGT GAC AGC CGA GTC CTG GAG AGG TAC CTC TTG
 Val Leu Gly Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu
 211 241
 GAG GCC AAG GAG GCC GAG AAT ATC ACG ACG GGC TGT GCT GAA CAC TGC AGC TTG AAT GAG
 Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu
 271 301
 AAT ATC ACT GTC CCA GAC ACC AAA GTT AAT TTC TAT GCC TGG AAG AGG ATG GAG GTC GGG
 Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg Met Glu Val Gly
 331 361
 CAG CAG GCC GTA GAA GTC TGG CAG GGC CTG GCC CTG CTG TCG GAA GCT GTC CTG CGG GGC
 Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly
 391 421
 CAG GCC CTG TTG GTC AAC TCT TCC CAG CCG TGG GAG CCC CTG CAG CTG CAT GTG GAT AAA
 Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys
 451 481
 GCC GTC AGT GGC CTT CGC AGC CTC ACC ACT CTG CTT CGG GCT CTG GGA GCC CAG AAG GAA
 Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu
 511 541
 GCC ATC TCC CCT CCA GAT GCG GCC TCA GCT GCT CCA CTC CGA ACA ATC ACT GCT GAC ACT
 Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr Ala Asp Thr
 571 601
 TTC CGC AAA CTC TTC CGA GTC TAC TCC AAT TTC CTC CGG GGA AAG CTG AAG CTG TAC ACA
 Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr
 +166 631 661
 GGG GAG GCC TGC AGG ACA GGG GAC AGA TGA CCA GGT GTG TCC ACC TGG GCA TAT CCA CCA
 Gly Glu Ala Cys Arg Thr Gly Asp Arg End
 691 721
 CCT CCC TCA CCA ACA TTG CTT GTG CCA CAC CCT CCC CCG CCA CTC CTG AAC CCC GTC GAG
 GGG

EPO 125

XbaI ▼ -22 62
 GA CTC TCA GCC TGG CTA TCT GTT CTA GAA TGT CCT GCC TGG CTG TGG CTT CTC CTG TCC CTG
 Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu
 92 +1 122
 CTG TCG CTC CCT CTG GGC CTC CCA GTC CTG GGC GCC CCA CCA CGC CTC ATC TGT GAC AGC
 Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu Ile Cys Asp Ser
 KpnI 152 182
 CGA GTC CTG GAG AGG TAC CTC TTG GAG GCC AAG GAG GCC GAG AAT ATC ACG ACG GGC TGT
 Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys
 212 242
 GCT GAA CAC TGC AGC TTG AAT GAG AAT ATC ACT GTC CCA GAC ACC AAA GTT AAT TTC TAT
 Ala Glu His Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr
 +55 ▼ 272 302
 GCC TGG AAG AGG ATG GAG GTG AGT TCC TTT TTT TTT TTT TTT CCT TTC TTT TGG AGA ATC
 Ala Trp Lys Arg Met Glu
 TCA TTT GCG AGC CTG ATT TTG G

FIG. 4




FIG. 5




FIG. 6




FIG. 7

FIG. 8a




FIG. 8b





FIG. 9





European Patent
Office

EUROPEAN SEARCH REPORT

Application number

EP 87 30 8130

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|---|--|---|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int. Cl.4) |
| X | WO-A-8 603 520 (GENETICS INSTITUTE INC.) * Whole document * | 1, 2, 4, 5, 6, 7, 8 | C 12 N 15/00 C 12 P 21/02 C 12 N 5/00 |
| Y | --- | 3 | |
| Y | GENE, vol. 38, no. 1/3, 1985, pages 111-118, Elsevier Science Publishers, Amsterdam, NL; T.V. RAMABHADRAN et al.: "High-level expression of the bovine growth hormone gene in heterologous mammalian cells" * Whole document * | 3 | |
| P, X | --- EP-A-0 236 059 (SNOW BRAND MILK PRODUCTS) * Whole document * | 1, 5, 6 | TECHNICAL FIELDS SEARCHED (Int. Cl.4) C 12 N C 12 P A 01 K |
| A | --- GB-A-2 171 304 (CHUGAI SEIYAKU K.K.) | | |
| A | --- WO-A-8 604 068 (GENETICS INSTITUTE INC.) ----- | | |
| The present search report has been drawn up for all claims | | | |
| Place of search THE HAGUE | | Date of completion of the search 03-10-1987 | Examiner DESCAMPS J.A. |
| CATEGORY OF CITED DOCUMENTS | | | |
| X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | |